Drug profile · INN
blinatumomab
BLINCYTO
blinatumomab (BLINCYTO) is a t cell surface glycoprotein cd3 cross-linking agent. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Drug details — blinatumomab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 18
- Data quality
- 0.84
Quick answer
blinatumomab (BLINCYTO) is a t cell surface glycoprotein cd3 cross-linking agent. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
T cell surface glycoprotein CD3 cross-linking agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is blinatumomab?
blinatumomab (BLINCYTO) is a t cell surface glycoprotein cd3 cross-linking agent. Associated with Amgen. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for blinatumomab?
BLINCYTO is a marketed brand name for blinatumomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of blinatumomab?
blinatumomab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.